Greenspace Health and LifeStream Behavioral Center, a leading nonprofit provider of behavioral health and social services in Central Florida, have partnered to implement Measurement-Based Care (MBC) across LifeStream’s full continuum of programs. The collaboration will leverage data-driven insights and patient-reported outcome measures (PROMs) within the care process to improve service quality and clinical outcomes for thousands of individuals served across Lake, Citrus, Sumter, Orange,

Nano X Imaging Ltd, a leader in innovative medical imaging technology, today announced that its U.S.-based subsidiary, Nanox Impact Inc., has signed a new distribution agreement with Digital X-Ray Imaging Inc., a leading diagnostic imaging provider serving healthcare facilities across Arkansas. The agreement will support the deployment of the Nanox.ARC, an FDA-cleared, multisource digital tomosynthesis system that makes 3D imaging possible in more clinical settings at a lower cost a

Etiometry, a leader in AI-driven clinical intelligence, today announced it has received FDA clearance (K254066) for the first-ever solution for automation of hospital-specific cardiogenic shock classification and tracking by directly utilizing data from physiologic monitoring, the Etiometry Cardiogenic Shock Tool. Cardiogenic shock remains a critical challenge, with delayed identification contributing to poor outcomes and persistently high mortality rates, despite advances in care.

Neuropacs™ Corp., an innovator in AI-enabled neurological imaging, today announced that the U.S. Food and Drug Administration has granted De Novo classification to neuropacs™, a diffusion MRI–based software application designed to assist clinicians in the evaluation of Parkinsonian syndromes. neuropacs™ is the first medical device classified by the FDA under the new category of “Parkinsonian syndrome diagnostic aid.” The software analyzes diffusio

Neuropacs™ Corp., an innovator in AI-enabled neurological imaging, today announced that the U.S. Food and Drug Administration has granted De Novo classification to neuropacs™, a diffusion MRI–based software application designed to assist clinicians in the evaluation of Parkinsonian syndromes. neuropacs™ is the first medical device classified by the FDA under the new category of “Parkinsonian syndrome diagnostic aid.” The software analyzes diffusio

Okami Medical, a medical technology company pioneering novel vascular embolization solutions, today announced the enrollment of the first patient in the ALPHA Registry, a prospective, multicenter registry evaluating the safety and effectiveness of the LOBO™ Vascular Occlusion System for patients suffering from a variety of peripheral vascular conditions, including arterial hemorrhage and pulmonary arteriovenous malformation. "We are honored to enroll the first patient in

Premier Radiology Services (Premier) is excited to announce the acquisition of Global Imaging Solutions (GLOBIS), a leading teleradiology group providing subspecialty imaging interpretations to outpatient imaging centers and orthopedic practices. The addition of GLOBIS further expands Premier’s subspecialized capabilities and strengthens its ability to support advanced diagnostic imaging needs nationwide. “Welcoming the GLOBIS team marks another exciting step for Premier

Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue

Boston Scientific Corporation (NYSE: BSX) today announced positive data from the HI-PEITHO global randomized clinical trial evaluating the use of the EKOS™ Endovascular System in patients with intermediate-risk pulmonary embolism (PE). The study met the composite primary endpoint, with data demonstrating that the EKOS system plus anticoagulation was superior to the current standard of care – anticoagulation alone – for the treatment of acute PE. Findings from the trial were

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the completion of an additional $6 million milestone-based convertible loan to Neurolief Ltd. (“Neurolief”). This second tranche investment was triggered by the recent U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for Neurolief's Proliv™Rx system